Soligenix (STU:DOA) EV-to-Revenue : 6.02 (As of May. 25, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Soligenix EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Soligenix's enterprise value is €0.65 Mil. Soligenix's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €0.11 Mil. Therefore, Soligenix's EV-to-Revenue for today is 6.02.

The historical rank and industry rank for Soligenix's EV-to-Revenue or its related term are showing as below:

STU:DOA' s EV-to-Revenue Range Over the Past 10 Years
Min: -15 Med: 5.17 Max: 841.47
Current: 15.22

During the past 13 years, the highest EV-to-Revenue of Soligenix was 841.47. The lowest was -15.00. And the median was 5.17.

STU:DOA's EV-to-Revenue is ranked worse than
66.76% of 1038 companies
in the Biotechnology industry
Industry Median: 8.22 vs STU:DOA: 15.22

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-25), Soligenix's stock price is €6.012. Soligenix's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.01. Therefore, Soligenix's PS Ratio for today is 601.20.

Soligenix EV-to-Revenue Historical Data

The historical data trend for Soligenix's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soligenix EV-to-Revenue Chart

Soligenix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

8.16

16.08

370.53

66.40

Soligenix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															10.35	-6.79	-2.92	-	20.71

Competitive Comparison of Soligenix's EV-to-Revenue

For the Biotechnology subindustry, Soligenix's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Soligenix's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soligenix's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Soligenix's EV-to-Revenue falls into.

Soligenix EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Soligenix's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	0.650	/	0.108
	=	6.02

Soligenix's current Enterprise Value is €0.65 Mil.
Soligenix's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.11 Mil.

Soligenix (STU:DOA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Soligenix's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	6.012	/	0.01
	=	601.20

Soligenix's share price for today is €6.012.
Soligenix's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01.

Soligenix EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Soligenix's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Soligenix (STU:DOA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soligenix Inc (STU:DOA) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

SNGX:USA

Address

29 Emmons Drive, Suite B-10, Princeton, NJ, USA, 08540

Website

https://www.soligenix.com

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Soligenix (STU:DOA) Headlines

No Headlines